Floxuridine
From Wikipedia, the free encyclopedia
Image:Floxuridine.png | |
Floxuridine
|
|
Systematic (IUPAC) name | |
5-fluoro-1-[4-hydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl]- 1H-pyrimidine-2,4-dione | |
Identifiers | |
CAS number | 50-91-9 |
ATC code | ? |
PubChem | 5790 |
DrugBank | APRD00692 |
Chemical data | |
Formula | C9H11FN2O5 |
Mol. weight | 246.193 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Floxuridine is an oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colectoral cancer.
Contents |
[edit] Pharmacology
Floxuridine, an analog of 5-Fluorouracil, is a fluorinated pyrimidine.
[edit] Meachanism of action
Floxuridine works because it is broken down by the body into its active form, which is the same as a metabolite of 5-Fluorouracil.
[edit] History
Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-fluorouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to Faulding, which became Mayne Pharma.
[edit] Suppliers
In the US the drug is supplied by Mayne Pharma as well as APP and Bedford.